Get notified when DARE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, and its auditor has included a going-concern explanatory paragraph.
- Delisting (new) — The company has received a formal delisting determination from Nasdaq and faces a hearing in late August 2026.
- Dilution (new) — Investors in this offering will suffer immediate and substantial dilution of $1.12 per share.
Dare Bioscience prices $12.0M primary offering at $1.37/share; net proceeds $5.4M
Filed August 17, 2026 · ~1 min read
Key Changes
-
high
Dare Bioscience is offering 4,085,687 common shares at $1.37 and 293,894 pre-funded warrants at $1.3699, plus concurrent private placement warrants.
The Offering verify on EDGAR → -
high
The company estimates net proceeds of approximately $5.4 million after fees and expenses, to be used for working capital and general corporate purposes.
Use of Proceeds verify on EDGAR → -
high
Investors in this offering will experience immediate dilution of $1.12 per share based on as adjusted net tangible book value.
Dilution verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade DARE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify